Israel
Index Globenewswire
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Rabu, 28 Mei 2025 - 20:54:01 Wib Globenewswire
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
Rabu, 28 Mei 2025 - 03:46:55 Wib Globenewswire
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
Kamis, 22 Mei 2025 - 04:04:00 Wib Globenewswire
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Kamis, 22 Mei 2025 - 04:02:24 Wib Globenewswire
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Senin, 19 Mei 2025 - 16:00:00 Wib Globenewswire
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
Senin, 19 Mei 2025 - 16:00:00 Wib Globenewswire
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
Senin, 19 Mei 2025 - 02:26:40 Wib Globenewswire
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
Selasa, 13 Mei 2025 - 00:57:04 Wib Globenewswire
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
Rabu, 07 Mei 2025 - 18:30:00 Wib Globenewswire
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Selasa, 08 April 2025 - 03:50:43 Wib Globenewswire
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Jumat, 28 Maret 2025 - 21:48:52 Wib Globenewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Selasa, 18 Februari 2025 - 18:30:00 Wib Globenewswire
Value of AI, Cloud Solutions Reign in Cellebrite’s 2025 Annual Industry Trends Survey
Selasa, 11 Februari 2025 - 21:00:00 Wib Globenewswire
Cellebrite’s Generative AI Innovations Deliver a Powerful Assistant to Expedite Investigations
Kamis, 06 Februari 2025 - 21:33:15 Wib Globenewswire
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in Major Parts of Europe and in Israel
Senin, 13 Januari 2025 - 13:30:00 Wib Globenewswire
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Jumat, 10 Januari 2025 - 21:00:00 Wib
